Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia |
Rejected |
Dasatinib |
2 |
LPI-JOR-LEB-KSA-TUN- |
KFSH & RC - R |
"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients " |
Completed |
Micafungin |
3b |
9463EC0001 |
NGHA-R |
"Randomized, Embedded, Multifactorial Adaptive Platform trial for Community- Acquired Pneumonia (REMAP-CAP)" |
Ongoing |
Ceftriaxone - Piperacillin Tazobactam - Azithromycin - Interferon β1-a - Hydrocortisone sodium suc... - Hydroxychloroquine - OSELTAMIVIR - Lopinavir-Ritonavir |
3 |
CT20/001/R |
NGHA-R |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition. |
Ongoing |
solifenacin succinate |
1, BE |
42767 |
Saudi Ajal |
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy subjects under fasting condition. |
Ongoing |
Enoxa / Enoxaparin |
3, BE |
21-2017 |
Saudi Ajal |
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. |
Ongoing |
Tacrolimus/ Prograf |
1, BE |
19-2017 |
Saudi Ajal |
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma |
Ongoing |
Sorafenib (Nexavar) |
3 |
RTOG 1112 |
KFSH & RC-R |
"Randomized clinical trial of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients" |
Ongoing |
DENOSUMAB |
3 |
20-610 |
King Abdullah Medical City (Makkah) |
"randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)" |
Completed |
Ambrisentan 5 mg |
3 |
AMB115811 |
KFMC |
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity |
Ongoing |
Ranibizumab |
3 |
CRFB002H2301 V 01 |
KFSH & RC-R |